| Identification | Back Directory | [Name]
Quinoxaline, 2-(4-methyl-1-piperazinyl)-3-[[5-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1,3,4-oxadiazol-2-yl]thio]- | [CAS]
2490542-33-9 | [Synonyms]
Bcl-2-IN-9
Quinoxaline, 2-(4-methyl-1-piperazinyl)-3-[[5-[4-[2-(4-morpholinyl)ethoxy]phenyl]-1,3,4-oxadiazol-2-yl]thio]- | [Molecular Formula]
C27H31N7O3S | [MOL File]
2490542-33-9.mol | [Molecular Weight]
533.65 |
| Hazard Information | Back Directory | [Uses]
Bcl-2-IN-9 is a novel proapoptotic Bcl-2 inhibitor with IC50 value of 2.9 μM and low cytotoxic. Bcl-2-IN-9 mediates apoptosis by down-regulating expression of Bcl-2 in cancer cells and has a high selectivity against leukemia cells[1]. | [IC 50]
Bcl-2: 2.9 μM (IC50, [1]) | [References]
[1] Yukari Ono, et al. Design and synthesis of quinoxaline-1,3,4-oxadiazole hybrid derivatives as potent inhibitors of the anti-apoptotic Bcl-2 protein. Bioorg Chem. 2020 Aug; 104: 104245. |
|
|